ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Recently, however, the DanGer Shock trial delivered a decisively positive result for Impella in highly selected patients with STEMI complicated by cardiogenic shock. On the strength of that trial, the ...

4 "The DanGer Shock RCT results provide the highest level of scientific evidence demonstrating that Impella CP increases survival in patients with cardiogenic shock secondary to STEMI, which led ...

The first clinical guidance for cardiogenic shock will be presented at the American College of Cardiology Scientific Session ...

Patients with severe heart failure or cardiogenic shock often require assistance from MCS devices such as venoarterial ...